Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2763204 | 0.88 | ACACB (0.47) | ACACBNPC1CYP1A2CYP2C9HPGD | |
| SCHEMBL16799587 | 0.87 | ALDH1A1 (0.47) | CYP1A2CYP2C9HPGDCYP2C19RAB9A | |
| SCHEMBL7187490 | 0.81 | ACACB (0.54) | ACACBNPC1CYP1A2CYP2C9HPGD | |
| SCHEMBL4319225 | 0.81 | ACACB (0.62) | ACACBNPC1CYP1A2CYP2C9HPGD | |
| SCHEMBL7182966 | 0.80 | ACACB (0.53) | ACACBNPC1CYP1A2CYP2C9HPGD | |
| SCHEMBL10411917 | 0.80 | ACACB (0.57) | ACACBNPC1CYP1A2CYP2C9HPGD | |
| SCHEMBL16799896 | 0.77 | ACACB (0.40) | ACACBNPC1CYP1A2CYP2C9HPGD | |
| SCHEMBL16799894 | 0.77 | ACACB (0.40) | ACACBNPC1CYP1A2CYP2C9HPGD | |
| SCHEMBL16799666 | 0.77 | ALDH1A1 (0.43) | ACACBCYP1A2CYP2C9HPGDCYP2C19 | |
| SCHEMBL13679738 | 0.76 | ACACB (0.36) | TRPM8ACACBNPC1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| WO-2016128771-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | WO | disclosed |
| US-20160107984-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2016-04-21 | — | — | US | disclosed |
| US-20160107984-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2016-04-21 | — | — | US | disclosed |
| US-20160107984-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2016-04-21 | — | — | US | disclosed |
| US-9120723-B2 | Modulator | CANBEX THERAPEUTICS LIMITED (GB) | 2015-09-01 | — | — | US | disclosed |
| US-9120723-B2 | Modulator | CANBEX THERAPEUTICS LIMITED (GB) | 2015-09-01 | — | — | US | disclosed |
| US-9120723-B2 | Modulator | CANBEX THERAPEUTICS LIMITED (GB) | 2015-09-01 | — | — | US | disclosed |
| US-20130123356-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2013-05-16 | — | — | US | disclosed |
| EP-2177503-A1 | MODULATORS OF CANNABINOID RECEPTORS | UCL Business PLC (GB) | 2010-04-21 | — | — | EP | disclosed |
| EP-2177503-A1 | MODULATORS OF CANNABINOID RECEPTORS | UCL Business PLC (GB) | 2010-04-21 | — | — | EP | disclosed |
| US-7696382-B2 | Modulator | UNIVERSITY COLLEGE LONDON (GB) | 2010-04-13 | — | — | US | disclosed |
| US-7696382-B2 | Modulator | UNIVERSITY COLLEGE LONDON (GB) | 2010-04-13 | — | — | US | disclosed |
| EP-1745011-B1 | MODULATORS OF CANNABINOID RECEPTORS | UCL BUSINESS PLC (GB) | 2009-09-30 | — | — | EP | disclosed |
| EP-1745011-B1 | MODULATORS OF CANNABINOID RECEPTORS | UCL BUSINESS PLC (GB) | 2009-09-30 | — | — | EP | disclosed |
| US-20080114062-A1 | Modulator | UNIVERSITY COLLEGE LONDON WOLFSON INSTITUTE FOR BIOMEDICAL RESEARCH (GB) | 2008-05-15 | — | — | US | disclosed |
| US-20080114062-A1 | Modulator | UNIVERSITY COLLEGE LONDON WOLFSON INSTITUTE FOR BIOMEDICAL RESEARCH (GB) | 2008-05-15 | — | — | US | disclosed |
| EP-1745011-A2 | MODULATORS OF CANNABINOID RECEPTORS | UCL Biomedica plc (GB) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005080316-A2 | MODULATORS OF CANNABINOID RECEPTORS | UCL BIOMEDICA PLC. (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114062-A1 | Modulator | CHRNA3, CHRM3, NR3C2 | TRPM8 491/4885ACACB 3036/4885NPC1 1099/4885 |
| US-20160107984-A1 | MODULATOR | CHRNA3, CHRNB3, CHRM3 | TRPM8 482/4885ACACB 3390/4885NPC1 2262/4885 |
| US-20130123356-A1 | MODULATOR | MRGPRX2, NR3C2, MC2R | TRPM8 49/4885ACACB 2315/4885NPC1 309/4885 |
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | HCN4, KCNJ4, KCNQ4 | TRPM8 98/4885ACACB 3843/4885NPC1 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.